# Antibiotic exposure exacerbates acute-on-chronic liver failure via gut microbiota imbalance and secondary liver lesion

**Authors:** Shujuan Yang, Jing Wang, Nan Yang, Juan Li, Li Jin, Yan Zhang, Hongli Wang, JianJun Fu, Tianyan Chen, Yingren Zhao, Yingli He

PMC · DOI: 10.1099/jmm.0.002045 · 2026-01-22

## TL;DR

Antibiotics worsen liver failure outcomes by disrupting gut bacteria balance, leading to more severe liver damage.

## Contribution

This study identifies gut microbiota dysbiosis as a mechanism linking antibiotic exposure to worse outcomes in acute-on-chronic liver failure.

## Key findings

- Antibiotic-exposed ACLF patients had lower survival rates compared to non-exposed patients.
- Antibiotic exposure in rats led to more severe hepatitis and higher alanine transaminase levels.
- Gut microbiota diversity decreased with antibiotic exposure, and specific bacterial families increased or decreased.

## Abstract

Introduction. The correlation between antibiotic exposure and adverse outcomes in patients with acute-on-chronic liver failure (ACLF) remains controversial, and the underlying mechanism is unclear.

Hypothesis/Gap Statement. This study hypothesizes that antibiotic exposure in ACLF patients alters gut microbiota, which affects the outcome of ACLF.

Aim. To explore the effect of antibiotic exposure on gut microbiota that affects the outcome of ACLF.

Methodology. A retrospective matched study of ACLF patients and the ACLF rat model was used to assess adverse outcomes associated with antibiotic exposure. The gut microbiota of the ACLF patients and the ACLF rat model were sequenced using the Illumina MiSeq platform.

Results. Twenty-three ACLF patients who were exposed to antibiotics and 46 matched controls who were not exposed to antibiotics were enrolled. The survival rates at 4, 12 and 24 weeks were significantly lower in the exposure group than in the non-exposure group. In the ACLF rat model, hepatitis in the antibiotic-exposure group became more severe, and the alanine transaminase levels were higher than those of the non-exposure group. The gut microbiota diversity was decreased in the ACLF patients with antibiotic exposure, and the proportions of Enterococcaceae and Peptostreptococcaceae were increased, while those of Lachnospiraceae, Bifidobacteriaceae and Bacteroidaceae were decreased. In the rat model, antibiotic exposure induced Gram-positive and Gram-negative bacterial eradication, and Klebsiella became the dominant micro-organism.

Conclusion. Antibiotic exposure aggravated hepatitis and had no survival benefit for ACLF. The underlying mechanism may be related to dysbiosis in the gut microbiota.

## Linked entities

- **Diseases:** hepatitis (MONDO:0002251)

## Full-text entities

- **Genes:** Cd24 (CD24 molecule) [NCBI Gene 25145] {aka Cd24a}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** enteritis (MESH:D004751), Liver Disease (MESH:D008107), hepatic abnormalities (MESH:D056486), ACLF (MESH:D065290), swelling (MESH:D004487), diabetes (MESH:D003920), oedema (MESH:C536897), diarrhoea (MESH:D003967), gut inflammation (MESH:D007249), fever (MESH:D005334), hepatitis A, C, D, E (MESH:D019701), liver failure (MESH:D017093), Bacterial infections (MESH:D001424), hypertension (MESH:D006973), endotoxemia (MESH:D019446), infection (MESH:D007239), Clostridium difficile infection (MESH:D003015), cholestasis (MESH:D002779), haemorrhages (MESH:D006470), bile duct hyperplasia (MESH:D001649), inflammatory bowel disease (MESH:D015212), MELD (MESH:D058625), Hepatic flare (MESH:D000067251), autoimmune disease or cancer (MESH:D009369), congestion (MESH:D002311), bloodstream infections (MESH:D018805), cirrhosis (MESH:D005355), coagulative necrosis (MESH:D001778)
- **Chemicals:** eosin (MESH:D004801), bilirubin (MESH:D001663), saline (MESH:D012965), LPS (MESH:D008070), pentobarbital (MESH:D010424), bile acid (MESH:D001647), Haematoxylin (MESH:D006416), cholesterol (MESH:D002784), glucose (MESH:D005947), formalin (MESH:D005557), metronidazole (MESH:D008795), ampicillin (MESH:D000667), neomycin (MESH:D009355), ammonia (MESH:D000641), vancomycin (MESH:D014640), creatinine (MESH:D003404), Freund's incomplete adjuvant (-)
- **Species:** Pseudomonadota (proteobacteria, phylum) [taxon 1224], Enterococcus (genus) [taxon 1350], Rattus norvegicus (brown rat, species) [taxon 10116], gut metagenome (species) [taxon 749906], Lactobacillus (genus) [taxon 1578], Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606], Parasutterella (genus) [taxon 577310], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], hepatitis C virus [taxon 11103], Bacteroidales (order) [taxon 171549], Enterobacteriaceae (enterobacteria, family) [taxon 543], Klebsiella (genus) [taxon 570], Human immunodeficiency virus (species) [taxon 12721]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12825262/full.md

---
Source: https://tomesphere.com/paper/PMC12825262